Solid Biosciences (SLDB) Stock
Biotech company developing gene therapy for muscle disease. Here's the price, business snapshot, and what's worth knowing about Solid Biosciences in September 2026.
Solid Biosciences Inc (ticker: SLDB) is a clinical-stage biotechnology company focused on developing gene therapy and other treatments for Duchenne muscular dystrophy (DMD), a severe neuromuscular disorder. The company’s work centres on delivering genetic payloads to address the underlying causes of DMD, but like many early-stage biotech firms, it has faced clinical and regulatory challenges that have contributed to share-price volatility. With a market capitalisation of about $467.99M, Solid Biosciences has limited or no commercial revenues and depends on successful clinical trials, regulatory approvals and potential partnerships or financing to progress. Investing in SLDB can offer exposure to high-reward science, yet carries material risks — clinical setbacks, manufacturing hurdles and dilution from fundraising are common. This summary is for educational purposes only and not personalised advice; investors should research the latest trial data, regulatory filings and the company’s financial position before considering any investment and be prepared for significant price swings and the possibility of losing capital.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Solid Biosciences' stock with a target price of $17.71, indicating good growth potential.
Financial Health
Solid Biosciences is managing its cash flow and assets reasonably well, but has room for improvement.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Gene therapy focus
The company targets the genetic root of Duchenne muscular dystrophy, a high-potential scientific approach — though clinical and safety hurdles can be significant.
Volatility and catalysts
Trial readouts, regulatory updates and financing moves are likely to drive price swings; these events can create both opportunities and sharp downside risks.
Market and funding needs
As a development-stage firm with limited revenues, progression depends on capital, partnerships and regulatory approvals — investors should assess funding plans carefully.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
